Intensity Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023; filed November 13, 2023. Intensity is a clinical-stage biotechnology company developing intratumoral cancer treatments, led by INT230-6. It has no approved products and has not generated product revenue.
Financial performance and position
- Revenue: None; the company reports no product or licensing revenue.
- Third-quarter results: Operating expenses were $2.49 million, including $1.35 million in R&D and $1.14 million in G&A. Net loss was $2.33 million, versus $1.77 million in Q3 2022. Basic and diluted loss per share was $0.17, versus $0.52.
- Nine-month results: Operating expenses were $4.97 million, down from $6.08 million in 2022. Net loss was $7.37 million, versus $6.07 million. A $2.26 million noncash loss on extinguishment of convertible debt and a $1.32 million preferred-stock deemed dividend contributed to the period’s reported loss attributable to common stockholders of $8.69 million. Loss per share was $1.26, versus $1.78.
- Cash flow: Operating activities used $6.26 million in the first nine months, compared with $3.84 million in 2022. Investing activities used $8.84 million, principally for Treasury bills. Financing activities provided $20.48 million, primarily from the IPO and overallotment.
- Liquidity: At September 30, cash and cash equivalents were $6.69 million and marketable Treasury bills were $8.96 million, or approximately $15.6 million combined. Management projected funding for its current operating plan through July 2025; the notes separately state funds should cover at least 12 months from issuance of the statements.
- Debt and balance sheet: Convertible notes and accrued interest converted into common stock at the IPO; no convertible note balance remained at quarter-end. Total liabilities were $0.90 million, including lease liabilities. Total assets were $16.82 million and stockholders’ equity was $15.91 million. Accumulated deficit was $47.34 million.
Material changes versus prior comparable periods
- Q3 operating expenses rose 41% year over year: R&D increased 16.5% and G&A increased 87.6%. Higher clinical/manufacturing preparation, public-company insurance, accounting and consulting costs contributed.
- For the first nine months, R&D fell 29.6%, mainly because enrollment in the IT-01 and IT-02 trials had been completed in 2022, reducing patient-care costs. G&A increased 8.0%, including higher public-company insurance and compensation costs.
- The June/July 2023 IPO and overallotment issued 4.485 million shares for $22.43 million gross proceeds. Preferred stock and convertible notes converted into common stock; common shares outstanding rose to 13.71 million from 3.41 million at year-end 2022.
- The company began investing IPO cash in short-term U.S. Treasury bills. Q3 interest income rose to $147,539 from $988 a year earlier.
Outlook, development, and risks
- Management expects substantial operating losses and expenses for the foreseeable future, including spending on clinical development, manufacturing, regulatory work, personnel and public-company operations. The company has no committed external funding source and may need further equity, debt, collaboration or other financing; additional financing could dilute shareholders or be unavailable on acceptable terms.
- INT230-6’s IT-01 trial enrolled 110 patients; the clinical study report was finalized in September 2023, with delivery to partners expected in Q4 2023. The IT-02 presurgical breast-cancer trial enrolled 91 patients; statistical analysis planning was finalized in Q3.
- The company reported FDA orphan-drug designation for INT230-6’s three active components for soft tissue sarcoma. It was preparing a Phase 3 sarcoma study, including manufacturing and assay work, and intended to submit an IND with the protocol in Q4 2023. It was also developing a Phase 2/3 presurgical triple-negative breast-cancer program. These are stated plans, not evidence of subsequent completion or outcomes.
- Material risks include clinical-trial results and timing, regulatory approval, manufacturing readiness, intellectual-property protection, competition and the need for additional capital. The filing also cites potential effects from the Israel conflict and possible risk to a patent held in Russia if payments are restricted.
- Management concluded disclosure controls were not effective as of September 30, 2023, citing a material weakness from insufficient segregation of duties and limited administrative staffing. Planned remediation includes additional reviews and resources; full remediation is not assured.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether the planned Q4 2023 FDA meeting, IND submission, manufacturing and assay validation occurred, and the current timelines and funding requirements for the sarcoma and breast-cancer programs.
- Whether the estimated runway through July 2025 remains valid as clinical and manufacturing spending evolves, and whether further financing is required.
- How management reconciles its July 2025 operating-plan runway with the notes’ statement that available funds cover at least 12 months from issuance.
- Progress in remediating the ineffective disclosure controls and the material weakness in segregation of duties.
- The cover page marks “No” for having filed all required Exchange Act reports during the preceding 12 months; investors should verify the filing status and any explanation in SEC records.